These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 6783287)
1. Effect of active and passive immunization on the development of experimental Pseudomonas aeruginosa pyelonephritis in mice. Petit JC; Sicard D; Bayo S; Daguet GL Can J Microbiol; 1981 Jan; 27(1):93-7. PubMed ID: 6783287 [TBL] [Abstract][Full Text] [Related]
2. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605 [TBL] [Abstract][Full Text] [Related]
3. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa. Mates A; Zand P J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979 [TBL] [Abstract][Full Text] [Related]
4. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Zaidi TS; Priebe GP; Pier GB Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743 [TBL] [Abstract][Full Text] [Related]
5. Divalent flagellin immunotherapy provides homologous and heterologous protection in experimental urinary tract infections in mice. Sabharwal N; Chhibber S; Harjai K Int J Med Microbiol; 2016 Jan; 306(1):29-37. PubMed ID: 26655680 [TBL] [Abstract][Full Text] [Related]
6. [Antigenic properties of Pseudomonas aeruginosa anatoxin and the protective action of antitoxic anti-Pseudomonas aeruginosa serum]. Podgornaia LG; Dziuban NF Zh Mikrobiol Epidemiol Immunobiol; 1986 Jun; (6):67-9. PubMed ID: 3092510 [TBL] [Abstract][Full Text] [Related]
7. Active and passive immunization with Pseudomonas aeruginosa ribosomal vaccines and antisera in the burned rat model. Lieberman MM; Walker HL; Ayala E; Chapa I J Surg Res; 1986 Feb; 40(2):138-44. PubMed ID: 3080639 [TBL] [Abstract][Full Text] [Related]
8. [Effect of the protective properties of antisera and immunoglobulin to antigens of Pseudomonas aeruginosa slime]. Zaĭdner IG; Stanislavskiĭ ES; Gladus MA Zh Mikrobiol Epidemiol Immunobiol; 1980 Oct; (10):52-7. PubMed ID: 6778023 [TBL] [Abstract][Full Text] [Related]
9. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia. Pennington JE; Pier GB; Sadoff JC; Small GJ Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209 [TBL] [Abstract][Full Text] [Related]
10. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines. Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018 [TBL] [Abstract][Full Text] [Related]
11. Systemic and topical protection studies using Pseudomonas aeruginosa flagella in an ocular model of infection. Rudner XL; Hazlett LD; Berk RS Curr Eye Res; 1992 Aug; 11(8):727-38. PubMed ID: 1424719 [TBL] [Abstract][Full Text] [Related]
12. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100 [TBL] [Abstract][Full Text] [Related]
13. Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein. Yushkova NA; Kholodkova EV; Korobova TS; Stanislavsky ES Acta Microbiol Hung; 1986; 33(2):147-56. PubMed ID: 3101393 [TBL] [Abstract][Full Text] [Related]
14. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine. Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894 [TBL] [Abstract][Full Text] [Related]
15. Passive immunisation against Pseudomonas aeruginosa recombinant flagellin in an experimental model of burn wound sepsis. Faezi S; Sattari M; Mahdavi M; Roudkenar MH Burns; 2011 Aug; 37(5):865-72. PubMed ID: 21334822 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model. Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242 [TBL] [Abstract][Full Text] [Related]
17. [Experimental study of the dynamics of the formation of protective antibodies to the antigens of the slime of Pseudomonas aeruginosa]. Iushkova NA; Stanislavskiĭ ES; Landsman NM Zh Mikrobiol Epidemiol Immunobiol; 1983 Mar; (3):78-83. PubMed ID: 6405564 [TBL] [Abstract][Full Text] [Related]
18. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein. Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845 [TBL] [Abstract][Full Text] [Related]
19. Antigenic relationship between the common antigen (OEP) of Pseudomonas aeruginosa and Vibrio cholerae. Hirao Y; Homma JY Infect Immun; 1978 Feb; 19(2):373-7. PubMed ID: 75846 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of properties of Pseudomonas aeruginosa recombinant outer membrane protein F (OprF)]. Zlygostev SA; Gataullin AG; Kaloshin AA; Mikhaĭlova NA; Zverev VV Zh Mikrobiol Epidemiol Immunobiol; 2006; (7):43-7. PubMed ID: 17297879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]